21 January 2026
Indo US Bio-Tech Limited has reported a substantial decline in its net profit for the third quarter of the financial year 2025-26 (Q3 FY26), with figures decreasing by 40.7 per cent to ₹299.66 lakhs. This compares to a net profit of ₹505.45 lakhs recorded in the corresponding quarter of the previous fiscal year (Q3 FY25).
The company’s revenue from operations also experienced a marginal decrease, falling by 3.2 per cent to ₹2,279.83 lakhs in Q3 FY26, down from ₹2,356.35 lakhs in Q3 FY25. The unaudited financial results for the quarter ended 31 December 2025 were recently approved by the Board of Directors.
Quarterly Financial Performance
A breakdown of the company’s financial performance for Q3 FY26, compared to Q3 FY25, highlights the shifts:
- Revenue from Operations: ₹2,279.83 lakhs (Q3 FY26) versus ₹2,356.35 lakhs (Q3 FY25), representing a 3.2% decline.
- Total Income: ₹2,280.33 lakhs (Q3 FY26) versus ₹2,358.27 lakhs (Q3 FY25), a 3.3% decrease.
- Net Profit: ₹299.66 lakhs (Q3 FY26) versus ₹505.45 lakhs (Q3 FY25), marking a 40.7% reduction.
- Basic Earnings Per Share (EPS): ₹1.49 (Q3 FY26) versus ₹2.52 (Q3 FY25), a 40.9% decrease.
Nine-Month Performance Overview
For the nine-month period ended 31 December 2025 (9M FY26), Indo US Bio-Tech Limited demonstrated revenue growth while its net profit declined:
- Revenue from Operations: ₹8,441.44 lakhs (9M FY26) versus ₹7,045.38 lakhs (9M FY25), indicating a 19.8% increase.
- Net Profit: ₹1,115.11 lakhs (9M FY26) versus ₹1,258.28 lakhs (9M FY25), a 11.4% decrease.
- Basic EPS: ₹5.56 (9M FY26) versus ₹6.28 (9M FY25), an 11.5% decrease.
Auditor’s Qualified Opinion
The statutory auditors have issued a qualified opinion on the financial results. This qualification pertains to the company’s incomplete assessment of the financial impact of new Labour Codes. The auditors noted that no provision had been made for potential increased liabilities due to the absence of actuarial valuation or reliable estimates.
Operational and Other Financial Highlights
During Q3 FY26, the company’s expense structure underwent several changes. Purchases significantly increased to ₹2,033.64 lakhs from ₹23.91 lakhs in Q3 FY25. Conversely, production expenses saw a decrease, falling to ₹1,560.49 lakhs from ₹1,637.34 lakhs. A positive change in inventories, amounting to ₹1,996.00 lakhs, contributed to cost management during the quarter.
Other financial metrics include an increase in tax expenses to ₹16.66 lakhs in Q3 FY26, compared to a negative ₹3.71 lakhs in Q3 FY25. Finance costs rose to ₹76.73 lakhs from ₹38.40 lakhs, reflecting higher borrowing costs. Other comprehensive income recorded a loss of ₹0.21 lakhs, an improvement from a loss of ₹1.13 lakhs in the corresponding quarter of the previous year.
Company Profile
Indo US Bio-Tech Limited operates primarily in the seed cultivation, processing, and trading sectors. The company maintains its registered office in Ahmedabad, Gujarat, with its factory located in Village-Bardoli Kanthi, Gandhinagar district. Its paid-up equity share capital remains ₹2,005.20 lakhs, with a face value of ₹10 per share.
Discussion